Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Microbot Medical ( (MBOT) ) is now available.
On July 22, 2025, Microbot Medical Inc. announced the appointment of Christina Bailey as the new Vice President of Sales, highlighting her extensive experience in medical device sales and leadership roles at major companies. This strategic move is expected to bolster the company’s commercial efforts as it prepares for the anticipated launch of its LIBERTY Endovascular Robotic System, which is pending FDA clearance.
The most recent analyst rating on (MBOT) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics to improve patient care globally. The company has developed the world’s first single-use, fully disposable endovascular robotic system, aiming to overcome traditional barriers in accessing advanced robotic systems.
Average Trading Volume: 1,606,714
Technical Sentiment Signal: Buy
Current Market Cap: $89.85M
See more insights into MBOT stock on TipRanks’ Stock Analysis page.